ATE362362T1 - Zusammensetzung von einem ppar-alpha agonisten und metformin zur behandlung von obesitas - Google Patents
Zusammensetzung von einem ppar-alpha agonisten und metformin zur behandlung von obesitasInfo
- Publication number
- ATE362362T1 ATE362362T1 AT03780062T AT03780062T ATE362362T1 AT E362362 T1 ATE362362 T1 AT E362362T1 AT 03780062 T AT03780062 T AT 03780062T AT 03780062 T AT03780062 T AT 03780062T AT E362362 T1 ATE362362 T1 AT E362362T1
- Authority
- AT
- Austria
- Prior art keywords
- metformin
- ppar
- obesitas
- treatment
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02292940A EP1424070A1 (de) | 2002-11-28 | 2002-11-28 | Zusammensetzung von einem PPAR-alpha Agonisten und Metformin zur Senkung des Serumtriglyceridspiegels |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE362362T1 true ATE362362T1 (de) | 2007-06-15 |
Family
ID=32241358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03780062T ATE362362T1 (de) | 2002-11-28 | 2003-11-26 | Zusammensetzung von einem ppar-alpha agonisten und metformin zur behandlung von obesitas |
Country Status (22)
Country | Link |
---|---|
US (2) | US20060142397A1 (de) |
EP (2) | EP1424070A1 (de) |
JP (1) | JP2006508995A (de) |
CN (1) | CN1777417B (de) |
AT (1) | ATE362362T1 (de) |
AU (1) | AU2003288175B2 (de) |
BR (1) | BR0316810A (de) |
CA (1) | CA2507894C (de) |
CY (1) | CY1106749T1 (de) |
DE (1) | DE60313886T2 (de) |
DK (1) | DK1569634T3 (de) |
EA (1) | EA009772B1 (de) |
ES (1) | ES2287546T3 (de) |
HK (1) | HK1077755A1 (de) |
MA (1) | MA27553A1 (de) |
MX (1) | MXPA05005707A (de) |
NO (1) | NO20052549L (de) |
PT (1) | PT1569634E (de) |
SI (1) | SI1569634T1 (de) |
TN (1) | TNSN05148A1 (de) |
WO (1) | WO2004047831A2 (de) |
ZA (1) | ZA200504345B (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
EP1457206A1 (de) * | 2003-03-13 | 2004-09-15 | Fournier Laboratories Ireland Limited | Kombinierte Verwendung von einem Fibrat und von Orlistat zur Behandlung von Obesitas |
EP1559419A1 (de) * | 2004-01-23 | 2005-08-03 | Fournier Laboratories Ireland Limited | Pharmazeutische Darreichungsformen enthaltend Metformin und ein Fibrat, sowie deren Herstellungsprozesse |
FR2896160B1 (fr) * | 2006-01-13 | 2008-04-25 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agonistes du ppar alpha. |
US8883721B2 (en) * | 2009-05-12 | 2014-11-11 | Mcgill University | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
US9724381B2 (en) | 2009-05-12 | 2017-08-08 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
WO2011159917A2 (en) | 2010-06-16 | 2011-12-22 | The Administrators Of The Tulane Educational Fund | Growth hormone secretatogue receptor antagonists and uses thereof |
FR3050112B1 (fr) * | 2016-04-15 | 2020-09-04 | Soc Civ Immobiliere Gecinq | Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques |
CN107496397A (zh) * | 2016-06-14 | 2017-12-22 | 重庆安格龙翔医药科技有限公司 | 一种二甲双胍与非诺贝酸的复合物及其制剂 |
FR3056908B1 (fr) * | 2016-09-30 | 2019-04-19 | Nashpharm | Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie |
CN111374093A (zh) * | 2018-12-28 | 2020-07-07 | 高倩 | 超级肥胖小鼠的构建与鉴定方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT323195B (de) * | 1973-03-16 | 1975-06-25 | Hurka Wilhelm | Verfahren zur herstellung neuer salze von biguaniden |
FR2275199A1 (fr) * | 1974-06-19 | 1976-01-16 | Cerpha | (chloro-4 phenoxy) isobutyrate de dimethylbiguanide, son procede de preparation et medicaments contenant ce produit comme principe actif |
US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
CA2244831A1 (en) * | 1996-02-02 | 1997-08-07 | John T. Olson | Method of treating diabetes and related disease states |
EP0930882A2 (de) * | 1996-08-02 | 1999-07-28 | Institut Pasteur De Lille | Vorbeugung oder behandlung von typ 2 diabetes oder kardiovaskulärer erkrankung mit ppar modulatoren |
FR2774591B1 (fr) * | 1998-02-12 | 2000-05-05 | Lipha | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
US5942500A (en) * | 1998-04-27 | 1999-08-24 | Perry; Stephen C. | Dietary composition to reduce dietary fats |
FR2796940B1 (fr) * | 1999-07-26 | 2005-04-08 | Lipha | Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
US6498193B2 (en) * | 1999-12-22 | 2002-12-24 | Trustees Of Dartmouth College | Treatment for complications of type 2 diabetes |
US6569879B2 (en) * | 2000-02-18 | 2003-05-27 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
US20030092736A1 (en) * | 2001-05-30 | 2003-05-15 | Cheng Peter T. | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
US20050101542A1 (en) * | 2002-08-20 | 2005-05-12 | Regents Of The University Of California | Combination therapy for controlling appetites |
-
2002
- 2002-11-28 EP EP02292940A patent/EP1424070A1/de not_active Withdrawn
-
2003
- 2003-11-26 ES ES03780062T patent/ES2287546T3/es not_active Expired - Lifetime
- 2003-11-26 DK DK03780062T patent/DK1569634T3/da active
- 2003-11-26 CN CN2003801044454A patent/CN1777417B/zh not_active Expired - Fee Related
- 2003-11-26 US US10/536,660 patent/US20060142397A1/en not_active Abandoned
- 2003-11-26 AT AT03780062T patent/ATE362362T1/de active
- 2003-11-26 AU AU2003288175A patent/AU2003288175B2/en not_active Ceased
- 2003-11-26 SI SI200330898T patent/SI1569634T1/sl unknown
- 2003-11-26 MX MXPA05005707A patent/MXPA05005707A/es active IP Right Grant
- 2003-11-26 JP JP2004554485A patent/JP2006508995A/ja active Pending
- 2003-11-26 WO PCT/EP2003/013302 patent/WO2004047831A2/en active IP Right Grant
- 2003-11-26 EA EA200500691A patent/EA009772B1/ru not_active IP Right Cessation
- 2003-11-26 DE DE60313886T patent/DE60313886T2/de not_active Expired - Lifetime
- 2003-11-26 PT PT03780062T patent/PT1569634E/pt unknown
- 2003-11-26 CA CA2507894A patent/CA2507894C/en not_active Expired - Fee Related
- 2003-11-26 EP EP03780062A patent/EP1569634B8/de not_active Expired - Lifetime
- 2003-11-26 BR BR0316810-7A patent/BR0316810A/pt not_active IP Right Cessation
-
2005
- 2005-05-26 MA MA28301A patent/MA27553A1/fr unknown
- 2005-05-26 NO NO20052549A patent/NO20052549L/no not_active Application Discontinuation
- 2005-05-27 ZA ZA200504345A patent/ZA200504345B/en unknown
- 2005-05-27 TN TNP2005000148A patent/TNSN05148A1/fr unknown
- 2005-11-08 HK HK05109941A patent/HK1077755A1/xx not_active IP Right Cessation
-
2007
- 2007-07-20 CY CY20071100972T patent/CY1106749T1/el unknown
-
2010
- 2010-02-12 US US12/705,155 patent/US20100144874A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1077755A1 (en) | 2006-02-24 |
US20100144874A1 (en) | 2010-06-10 |
ES2287546T3 (es) | 2007-12-16 |
BR0316810A (pt) | 2005-10-18 |
PT1569634E (pt) | 2007-08-22 |
DE60313886T2 (de) | 2008-01-17 |
MXPA05005707A (es) | 2005-07-26 |
JP2006508995A (ja) | 2006-03-16 |
DK1569634T3 (da) | 2007-09-10 |
EA009772B1 (ru) | 2008-04-28 |
AU2003288175B2 (en) | 2008-11-13 |
EP1424070A1 (de) | 2004-06-02 |
MA27553A1 (fr) | 2005-10-03 |
WO2004047831A3 (en) | 2005-02-24 |
NO20052549L (no) | 2005-06-10 |
EA200500691A1 (ru) | 2005-12-29 |
CY1106749T1 (el) | 2012-05-23 |
CA2507894C (en) | 2011-01-04 |
WO2004047831A2 (en) | 2004-06-10 |
US20060142397A1 (en) | 2006-06-29 |
EP1569634B1 (de) | 2007-05-16 |
CA2507894A1 (en) | 2004-06-10 |
AU2003288175A1 (en) | 2004-06-18 |
DE60313886D1 (de) | 2007-06-28 |
ZA200504345B (en) | 2006-08-30 |
SI1569634T1 (sl) | 2007-10-31 |
CN1777417A (zh) | 2006-05-24 |
EP1569634A2 (de) | 2005-09-07 |
EP1569634B8 (de) | 2007-08-29 |
CN1777417B (zh) | 2010-10-06 |
TNSN05148A1 (fr) | 2007-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE345136T1 (de) | Cysteinprotease-hemmer mit 2-cyano-4-amino- pyrimidinstruktur und cathepsin-k-hemmender wirkung zur behandlung von entzündungen und anderen erkrankungen | |
ATE348649T1 (de) | Kombinationen von einem hemmer der sterol- absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen | |
ATE350375T1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen | |
DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
DE60319865D1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
DE60235083D1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
DE602004018338D1 (de) | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund | |
HK1077755A1 (en) | Use of a paralpha agonist and metformin for the treatment of obesity ppar-alpha | |
ATE346082T1 (de) | Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen | |
DE10082139T1 (de) | Zusammensetzung zur Behandlung von Reibungspaaren | |
ATE534635T1 (de) | N-pyrazinyl-phenylsulfonamide und deren verwendung zur behandlung von durch chemokine vermittelten krankheiten | |
DE60216495D1 (de) | Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung | |
DE602004025463D1 (de) | Verwendung von ciclesonide zur erhaltung des feinen teilchengrössenanteils von formoterol | |
ATE279386T1 (de) | Retinoide zur behandlung von emphysem | |
DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
DE602005016141D1 (de) | S-mirtazapin zur behandlung von hitzewallungen | |
DE60333205D1 (de) | Histaminika zur behandlung von allergischer rhinitis | |
DE50305507D1 (de) | Zusammensetzungen zur herstellung von aminoplasterzeugnissen | |
DE60206289D1 (de) | Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne | |
DE602005013287D1 (de) | Zusammensetzung zur behandlung von leder | |
DE69931487D1 (de) | Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation | |
DE69913380D1 (de) | Zusammensetzung zur behandlung von periodontalen erkrankungen | |
DE60208701D1 (de) | Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom | |
UY28145A1 (es) | Nuevos compuestos farmaceuticos | |
DE50308460D1 (de) | Verwendung von ambroxol zur behandlung von chronischen schmerzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1569634 Country of ref document: EP |